PTX-022
Sponsors
Palvella Therapeutics, Inc.
Conditions
AngiokeratomasBCCs in Gorlin Syndrome PatientsMicrocystic Lymphatic MalformationPachyonychia Congenita
Phase 2
Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita
CompletedNCT03920228
Start: 2019-04-01End: 2020-10-19Updated: 2024-08-29
CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome
CompletedNCT04893486
Start: 2021-05-06End: 2023-03-13Updated: 2024-08-29
Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
CompletedNCT05050149
Start: 2022-01-13End: 2022-12-15Updated: 2025-01-17
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
RecruitingNCT07552077
Start: 2026-04-01End: 2027-09-01Target: 15Updated: 2026-04-27
Phase 3
VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita
CompletedNCT04520750
Start: 2020-09-01End: 2022-12-15Updated: 2024-08-29
A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita
RecruitingNCT05643872
Start: 2022-11-15End: 2023-11-30Target: 45Updated: 2022-12-09